for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Valeritas Holdings Inc

VLRX.OQ

Latest Trade

0.67USD

Change

-0.05(-6.56%)

Volume

37,398

Today's Range

0.64

 - 

0.73

52 Week Range

0.55

 - 

11.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.71
Open
0.73
Volume
37,398
3M AVG Volume
5.87
Today's High
0.73
Today's Low
0.64
52 Week High
11.31
52 Week Low
0.55
Shares Out (MIL)
8.27
Market Cap (MIL)
5.92
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Valeritas Holdings - On Dec. 18, CFO Erick Lucera Resigned From His Position With Company, Effective Jan. 3, 2020

Valeritas Announces Third Quarter 2019 Financial Results

Valeritas Reduces Its Long-Term Debt Obligation Nearly 60% By Exchanging $25 Mln Of Debt For Series B Convertible Preferred Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Valeritas Holdings Inc

Valeritas Holdings, Inc. is a commercial-stage medical technology company. The Company is focused on developing technologies for Type 2 diabetes. The Company's product, the V-Go Wearable Insulin Delivery Device (V-Go), is an insulin delivery device that helps patients with Type 2 diabetes requiring insulin to maintain their target blood glucose goals. V-Go is a disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. The Company has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.

Contact Info

750 US Highway 202 Ste 600

+1.908.9279920

Executive Leadership

Peter J. Devlin

Independent Chairman of the Board

John Edward Timberlake

President, Chief Financial Officer, Director

Geoffrey Jenkins

Executive Vice President - Manufacturing, Operations and Research & Development

Melanie Hansen

Principal Accounting Officer, Interim Corporate Controller, Treasurer

Hokan Lars Ojert

Vice President - Sales

Key Stats

3.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-780.800

2017

-165.800

2018

-34.200

2019(E)

-9.365
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.20
Price To Book (MRQ)
0.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
155.93
LT Debt To Equity (MRQ)
154.69
Return on Investment (TTM)
-173.00
Return on Equity (TTM)
-114.61

Latest News

Latest News

BRIEF-Valeritas Says Entered Into Confidential Settlement Agreement With Roche Diabetes Care Inc

* VALERITAS HOLDINGS SAYS ON JULY 16, CO ENTERED INTO CONFIDENTIAL SETTLEMENT AGREEMENT WITH ROCHE DIABETES CARE INC - SEC FILING

BRIEF-Valeritas Reports Q4 Loss Per Share ‍$3.10​

* VALERITAS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Valeritas Announces V-Go Distribution Agreement In Italy With Movi SpA

* VALERITAS ANNOUNCES V-GO® DISTRIBUTION AGREEMENT IN ITALY WITH MOVI SPA

BRIEF-Valeritas Appoints Joseph Saldanha As Chief Business Officer

* VALERITAS APPOINTS JOSEPH SALDANHA AS CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:

BRIEF-Valeritas Sees Q4 Revenue About $5.6 Million

* SAYS EXPECTS FULL YEAR 2017 REVENUE TO REACH $20 MILLION, IN LINE WITH PRIOR GUIDANCE

BRIEF-Valeritas Holdings Files For Sale Of Up To 3.35 Mln Shares

* VALERITAS HOLDINGS INC FILES FOR SALE OF UP TO 3.35 MILLION SHARES OF CO'S COMMON STOCK BY ASPIRE CAPITAL FUND LLC - SEC FILING Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Valeritas Holdings Enters Into Common Stock Purchase Agreement With Aspire Capital Fund

* VALERITAS HOLDINGS SAYS ON JAN 7, 2018, CO ENTERED INTO COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND - SEC FILING

BRIEF-Valeritas Q3 revenue rises 4 pct

* Valeritas Holdings Inc - gross margin increased to 39.8% during Q3 of 2017 as compared to 35.6% during same period in 2016

BRIEF-Valeritas Holdings files for sale of up to 3.35 mln shares of co's common stock

* Valeritas Holdings Inc files for sale of up to 3.35 million shares of co's common stock by selling stockholder aspire Capital Fund Llc - SEC Filing Source text: (http://bit.ly/2hMmTJN) Further company coverage:

BRIEF-Valeritas Holdings files for mixed shelf of upto $20 mln

* Valeritas Holdings Inc files for mixed shelf of upto $20 million - SEC filing Source text for Eikon: (http://bit.ly/2hNk6jD) Further company coverage:

BRIEF-Valeritas Holdings ‍enters into a common stock purchase agreement with Aspire Capital Fund

* Valeritas Holdings Inc - Entered into a common stock purchase agreement ( "agreement") with Aspire Capital Fund LLC

BRIEF-Valeritas Holdings Inc Q2 loss per share $1.83

* Qtrly loss per share $1.83 Source text for Eikon: Further company coverage:

BRIEF-Valeritas appoints Peter Devlin to chairman of its board

* Valeritas appoints Peter Devlin to chairman of its board of directors

BRIEF-Valeritas' V-Go wearable insulin delivery device results in significant reductions in A1C

* Valeritas' V-Go wearable insulin delivery device results in significant reductions in A1C, insulin requirements and cost reductions in patients with diabetes Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up